The success of targeted cancer therapy is limited by drug resistance that can result from tumor genetic 1 heterogeneity. The current approach to address resistance typically involves initiating a new treatment after 2 clinical/radiographic disease progression, ultimately resulting in futility in most patients. Towards a poten-3 tial alternative solution, we developed a novel computational framework that uses human cancer profiling 4 data to systematically identify dynamic, pre-emptive, and sometimes non-intuitive treatment strategies that 5 can better control tumors in real-time. By studying lung adenocarcinoma clinical specimens and preclinical 6 models, our computational analyses revealed that the best anti-cancer strategies addressed existing resistant 7 subpopulations as they emerged dynamically during treatment. In some cases, the best computed treatment 8 strategy used unconventional therapy switching while the bulk tumor was responding, a prediction we con-9 firmed in vitro. The new framework presented here could guide the principled implementation of dynamic 10 molecular monitoring and treatment strategies to improve cancer control. 11 2 Introduction 12
(due to either known pharmacokinetic limitations or dose limiting toxicities) ( Fig. 4B ).
To better understand the efficacy of the combination therapy over time, we sought to classify which 160 initial tumor cell subpopulations could eventually lead to therapeutic failure when treated with different 161 concentrations of EGFR TKIs in combination with crizotinib, trametinib or vemurafenib. We defined the 162 evolutionary stability of a subpopulation as the worst-case evolutionary outcome, in each case where the 163 particular subpopulation is present upon treatment initiation. More precisely, the evolutionary stability is 164 the maximum eigenvalue of each evolutionary branch downstream of the subclone (SI, Section 3.2). This 165 approach provides an assessment of which subclones present in the initial tumor cell population are likely 166 to lead to overall progression (a positive evolutionary stability) versus those that lead to response (a neg-167 ative evolutionary stability) when treated with a particular combination therapy. Our analysis confirms 168 that progression-free response on combination therapies is sensitive to both EGFR TKI concentration and 169 dependent on whether pre-existent subpopulations are effectively targeted at these concentrations ( Fig. 4D   170 and Fig. S5-S7 ). Overall, this analysis revealed that combinations of two signal transduction inhibitors had 171 limited effectiveness in durably controlling resistance over a longer time horizon. 172 173 We next explored how the rational design of combination drug scheduling strategies could address this issue. 174 Experimental studies have recently proposed drug pulsing [30] or drug switching [10] as a strategy to delay 175 the growth of certain cancers. To this end, we proposed a novel methodology rooted in engineering principles 176 to design drug scheduling strategies that best control the growth and evolution of tumor cell populations. 177 In particular, we apply concepts from optimal and receding horizon control theory to our experimentally 178 integrated model of lung adenocarcinoma evolution to compute treatment strategies that minimize tumor 179 cell populations over time. Our algorithm allows for the specification of treatment design constraints such as 180 maximum dose, the time horizon over which the treatment strategy is applied and the switching horizon, that 181 is the minimum time over which one particular treatment can be applied. This algorithm can be extended 182 to include other drug related characteristics and treatment design constraints. In addition, the framework 183 allows for the analysis of tradeoffs between these aspects of the design space as well as others, such as how 184 robust the predicted treatment strategies are with respect to uncertainties in the model or perturbations in 185 drug dosages.
Engineering Drug Scheduling to Control Tumor Evolution
For a predetermined time and minimum switching horizon, we define an optimal control problem (SI, 187 Algorithm 1) and solve for the drug combination that best minimizes the existing tumor cell subpopulations 188 for every receding switching horizon. Given that any one polytherapy is unlikely to be simultaneously effective 189 against all subpopulations, the resulting optimal strategy, which maximizes the response of the tumor cells 190 present at every time horizon (SI, Mathematical Methods), is potentially one that switches between drug 191 combinations, at defined time points during the treatment course.
192
As proof-of-principle, we determined which drug scheduling regimens could maximally reduce different 193 initial tumor cell populations by solving our control problem for different allowable switching horizons over a 194 thirty day period (Fig. 5 ). The afatinib/trametinib combination was the optimal constant strategy for tumor 195 cell populations harboring the EGFR L858R,T790M mutation, and although this strategy invoked progression 196 free response in HGF-tumor cell populations, most L858R HGF+ tumor cell populations progressed on 197 the therapy over thirty days (Fig. 5A vs 5C and Fig. S6AB ). For the HGF-tumor population comprised 198 of 89% EGFR L858R , 10% EGFR L858R BRAF V600E and 1% EGFR L858R,T790M , the optimal constant strategy 199 provided overall response leaving a dominant EGFR L858R BRAF V600E tumor subpopulation present whereas 200 the optimal ten day switching strategy provided an enhanced response over the constant strategy by alter-201 nately targeting EGFR L858R and EGFR L858R, T790M tumor cell subpopulations (Fig. 5B ). In the case of the 202 HGF treated tumor cell distribution consisting of 90% EGFR L858R and 10% EGFR L858R,T790M , a constant 203 combination of afatinib/trametinib was effective against the EGFR L858R,T790M , HGF+ subpopulation de- More generally, the optimal constant strategies determined by our algorithm are combinations that best 209 minimize existing tumor cell subpopulations at every switching horizon. In particular, a greater reduction in 210 tumor cells can be achieved by switching between therapies that alternately target different subpopulations, 211 even while there is overall response in the tumor (Fig. 5A ). This finding suggests a non-intuitive approach to 212 the clinical management of solid tumors that would represent a departure from the current standard clinical practice. Our model suggests an advantage to switching treatments pro-actively even during a bulk tumor 214 response, while the current paradigm in the field is to switch from the initial treatment to a new drug(s) 215 only after there is clear evidence of radiographic or clinical progression on the initial treatment.
216
To understand the potential benefits of switching strategies in tumors with different initial genetic hetero-217 geneity, we computed the optimal switching strategies for a subset of tumor cell distributions and compared 218 them to their corresponding computed optimal constant strategies. We found that the larger the number 219 of subclones present in the initial tumor, the more beneficial even a small number of switches could be 220 for overall tumor cell population control ( Fig. 6A and Fig. S8A ). For a highly heterogeneous tumor cell 221 population comprised of HGF treated 89% EGFR L858R , 10% EGFR L858R BRAF V600E , 1% EGFR L858R,T790M 222 mutations, the predicted fifteen day switching therapy (afatinib/trametib followed by erlotinib/crizotinib) 223 provides an immediate benefit versus the predicted constant treatment strategy (afatinib/trametinib), yield-224 ing a 10-fold decrease in final tumor population. By contrast, for a more homogeneous tumor consisting 225 of 90% EGFR L858R , 10% EGFR L858R,T790M , the optimal predicted 30, 15 and 10 day switching strategies 226 are indistinguishable from the constant therapy strategy for population control. Our predictions indicate 227 that a similar 10-fold reduction in final population (similar to that achieved in the heterogeneous tumor 228 instance analyzed above) is achieved only with a more rapid, five day switching strategy for this more ho-229 mogeneous tumor population (afatinib/trametinib, then alternating between erlotinib/trametinib and afa-230 tinib/vemurafenib). These findings emphasize our results that while polytherapy may a provide response 231 in some subsets of tumor cell populations, it provides only a temporary or no response in heterogeneous or 232 MET activated tumors; in these cases, even minimal therapy switching can provide an immediate and more 233 substantial benefit for overall tumor population control. 
Robustness Analysis of Switching Strategies

235
Motivated by studies indicating that tissue to plasma ratios for certain drugs such as erlotinib can be low [31], 236 we sought to computationally explore how dose reductions of TKI combinations could affect the evolution of 237 tumor cell populations. This is a particularly relevant clinical issue, as many drugs when used in combination 238 often require a reduction in the recommended monotherapy dose due to toxicity of the dual drug therapy 239 in patients. To examine this question, we simulated the optimal switching strategies corresponding to 30, 240 15, 10, 5 and 1 day switching horizons subject to EGFR TKI dose reductions for a set of initial tumor 241 cell populations and studied the effects on the final and average tumor populations over the course of the 242 treatment (SI, Mathematical Methods).
243
For a tumor with a smaller number of initial subclones, such as one comprised of 90% EGFR L858R 244 and 10% EGFR L858R,T790M , all switching strategies induced a response for EGFR TKI dose reductions of 245 up to 50% (Fig. 6A ). In contrast, with the more complex HGF treated tumor cell population comprised 246 of 89% EGFR L858R , 10% EGFR L858R BRAF V600E , 1% EGFR L858R,T790M , only combination strategies with 247 switching horizons of 10 day or shorter induced a response ( Fig. 6B) . Notably, we observed that the shorter 248 the switching horizon, the higher dose reduction that could be supported while still maintaining a progression 249 free response ( Fig. 6B and Fig. S8B ). We observed this phenomenon more generally when we simulated 250 different tumor cell initial distributions ( Fig. 6C ). Thus, we find that the greater number of subclones 251 present in the initial tumor, the greater the benefit there is in increasing switching frequency in terms of the 252 achieving robustness to perturbations in EGFR TKI drug concentration. Motivated by the results of our treatment strategy algorithm, we tested drug scheduling strategies on select 255 tumor subpopulations in an in vitro model of EGFR mutant lung adenocarcinoma. Specifically, we syn-256 thesized the optimal treatment strategy for a heterogeneous HGF treated tumor cell population consisting 257 of 89% EGFR L858R , 10% EGFR L858R BRAF V600E , 1% EGFR L858R,T790M , and imposed a constraint that at 258 most one switch could occur, as a starting point to simulate what might be most clinically feasible. The 259 resulting optimal treatment strategy predicted by our modeling, consisting of the erlotinib/crizotinib (days 260 0-5) followed by the afatinib/trametinib (days 5-30) combination, was shown to elicit the best response in 261 vitro, validating our predictive model ( Fig. 7B ).
262
To show how a delay in the switching time might affect response to therapy, we tested equivalent initial 263 tumor cell populations but changed the treatment strategy to start the afatinib/trametinib combination at 264 day 10 instead of at day 5. This resulted in worse overall response than the 5 day switching regimen ( Fig.   265 7B). The corresponding model simulation highlights that although the erlotinib/crizotinib combination effec-266 tively targeted the HGF treated EGFR L858R mutation during the first 10 days, it allowed the HGF treated 267 EGFR L858R, T790M subclone to dominate for a longer period of time, thereby impeding overall response. One of the fundamental challenges in the principled design of combination therapies is the pre-existence 270 and temporal expansion of intratumor genetic heterogeneity that can often lead to rapid resistance with 271 first-line targeted therapies. To address this problem, we sought to develop a new modeling framework to 272 systematically design principled tumor monitoring and therapeutic strategies. We applied a receding horizon 273 optimal control approach to an evolutionary dynamics and drug response model of lung adenocarcinoma 274 that was identified from experimental and clinical data. Based on the clinical and experimental data, our 275 computational method generated optimal drug scheduling strategies for a comprehensive set of initial tumor 276 cell subpopulation distributions.
277
Our initial insight was that constant drug combination strategies that guarantee progression free response 278 for tumor cell populations with considerable heterogeneity and/or MET activation, required EGFR TKI 279 concentrations that were considerably higher than are typically clinically feasible. At clinically relevant doses, 280 these constant combination strategies were not effective against all tumor cell subpopulations and inevitably, 281 those subpopulations with even slight evolutionary advantages could undergo clonal expansion and cause 282 resistance. To overcome this issue, we used our algorithm to generate optimal drug scheduling strategies that 283 could preempt the outgrowth of these subpopulations over fixed switching periods, and showed that these 284 strategies outperformed constant combination strategies for most tumor cell subpopulation distributions. 285 Notably, our computational analysis showed there was more benefit in applying switching strategies in 286 the context of increasing pre-existing genetic heterogeneity and these switching strategies provided more 287 robustness guarantees in the presence of perturbations in drug concentrations that can occur in patients. We 288 demonstrated successful in vitro validation of our optimal control approach for selected tumor subpopulation 289 distributions. In particular, for an in vitro analog of our clinical case, a non-intuitive combination therapy 290 switching strategy offered better tumor control than constant treatment strategies. 291 We found that the most effective drug scheduling strategies were ones that addressed existing subpopu-292 lations as they emerged during the course of the treatment, even during a bulk tumor response. In contrast, 293 current standard of care clinical practice is generally to delay switching to second-line therapy until after 294 there is clear evidence of radiographic or clinical progression. Our approach suggests a paradigm shift that 295 would require regular monitoring of an individual patient's tumor mutational status, for instance by muta-296 tional analysis of plasma cell-free circulating tumor DNA, so-called "liquid biopsies" [32, 33, 34, 35, 36] . Our 297 modeling strategy could potentially synthesize this genetic information to yield both the design and priori-298 tization of specific drug regimens and the optimal time for clinical deployment, informed by the molecular 299 findings in a particular patient. Such treatments may need to be applied (non-intuitively) during the initial 300 tumor response, instead of later during therapy or after drug resistance is readily apparent by standard clini-301 cal measures in some cases. We envision that our approach could help contribute to the shift from a reactive 302 to pro-active, dynamic management paradigm in solid tumor patients in the molecular era. Drug scheduling 303 strategies synthesized by the algorithm for the initial tumor cell population could be adapted to account for 304 genetic alterations that are detected by the analysis of serial liquid (or tumor) biopsies, leading to a dynamic 305 learning model through iterative refinements; as such, the model could suggest more effective strategies with The details of mathematical models and experimental methods may be found in SI Mathematical Meth-317 ods. The mathematical model of lung adenocarcinoma growth mutation and selection by small molecule 318 inhibitors was formulated as system of ordinary differential equations (ODEs). The treatment strategy algo-rithm was formulated as a receding horizon optimal control problem with the objective of minimizing lung Figure 6 : Exploring the robustness of treatment strategies through model simulation. (A) Switching strategies are more beneficial to tumor cell populations with more initial heterogeneity. (Left) Fold change in final lung adenocarcinoma tumor cell populations at day 30 versus day 0 over the course of the optimal 30, 15, 10, 5, 3, and 1 day treatment strategies solved by algorithm 1 (SI, Section 2.2) and normalized by fold change in final tumor cell population for the constant 30 day treatment strategy for an initial tumor cell population comprised of (90% EGFR L858R , 10% H1975 EGFR L858R,T790M ) and another comprised of (89% EGFR L858R , 10% BRAF V600E ,1% EGFR L858R,T790M ) subclones. (Right) Sum of fold change for the final lung adenocarcinoma populations (SI, Equation S5) for select initial tumor cell distributions (SI, Table 1 ) and their corresponding optimal 30, 15, 10, 5, 3, and 1 day treatment strategies, categorized by the number of subclones in the initial tumor cell population. Smaller fold change sums indicate that more switching is beneficial to reduce final populations, whereas larger fold changes indicate that more switching does not necessarily help in reducing the final tumor populations. (B) EGFR TKI dose perturbations. (Left) Fold change in number of lung adenocarcinoma cells between day 30 and day 0, as a function of percent EGFR TKI dose reduction for the optimal 30, 15, 10, 5 and 1 day strategies solved by algorithm 1 (SI, Section 2.2) for tumor cell populations indicated above. The shaded areas indicate the regions of the perturbation space where the treatment strategy reduces the initial tumor cell population by more than 30% (response, light blue), increases the size of the original tumor population size by more than 20% (progression, red), or maintains the original tumor population size between the two (stability, white). (Right) Bar graphs indicate the maximum reduction in EGFR TKI dose supported by the optimal strategy such that there is still reduction in tumor size at day 30 with respect to day 0 for the V600E and the pretreatment MET tumor. (C) The average maximum percent EGFR TKI dose reduction supported before progression for lung adenocarcinoma tumors with different number of initial tumor cell subpopulations and for predicted optimal 30, 15, 10, 5, and 1 day switching strategies. Figure 7 : Engineering optimal treatment strategies for concurrent, clonal genetic alterations in EGFR-mutant lung adenocarcinoma and predicting their therapeutic impact. (A) Simulations of the optimal treatment strategy predicted by algorithm 1 (SI, Section 2.2) consisting of 1.5 µM erlotinib+0.5 µM crizotinib for days (0-5) followed by 0.5 µM afatinib+0.5 µM trametinib for days (5-30); the same strategy but with the switch occurring at day 10 and, constant strategies of 0.5 µM afatinib+0.5 µM trametinib or 1.5 µM erlotinib+0.5 µM crizotinib for 30 days, for an initial tumor cell population of 89% EGFR L858R , 10% EGFR L858R BRAF V600E , 1% EGFR L858R,T790M , HGF treated. (B) Evolution experiment shows that the predicted strategy for an initial tumor cell population of 89% EGFR L858R , 10% EGFR L858R BRAF V600E , 1% EGFR L858R,T790M , treated with 50 ng/ml HGF, is optimal. Overlaid numbers indicate the relative cell density of each well at day 30 compared to the erlotinib+crizotinib well (magenta). Computational simulations in (A) show that the predicted optimal strategy has the greatest reduction in tumor cells in vitro (B, red) compared to the same strategy with a 10 day switch (yellow). A simulation of the model predicts that a constant treatment of afatinib+trametinib produces little change in number of tumor cells (B, blue) and that a constant treatment of erlotinib+crizotinib predicts the exponential outgrowth of the initial EGFR L858R,T790M MET amplified subpopulation, experimentally validated in (B, magenta).
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1 Mathematical Methods
Evolutionary Dynamics Model of NSCLC
The quasispecies model [1] was originally developed to describe the dynamics of populations of self replicating macromolecules undergoing mutation and selection. We choose this model for its relative simplicity and its ability to capture the salient features of the evolutionary dynamics of a simplified generic disease model. The following adaptation incorporates the effects of small molecule inhibitors and describes the growth, mutation and evolution of non small cell lung adenocarcinoma populations:
where x i 2 R + is the concentration of a NSCLC subpopulation i,`k 2 R + is a small molecule inhibitor concentration (assumed to remain at constant concentrations throughout), r i is the growth rate for each cell
x i , and q ik is the probability that cell k mutates to cell i (note that q ii is the probability of no mutation occurring). Finally, the function i (`k) represents the pharmacodynamics of individual drugs`k or of individual EGFR TKIs (erlotinib or afatinib) in combination with fixed concentrations other small molecule inhibitors used in this study (0.5 µM crizotinib, 0.5 µM trametinib or 5 µM vemurafenib) with respect to the i-th NSCLC cell type, namely:
where`k 2 R + is the drug concentration, ik 2 R + is the saturation coefficient, K ik 2 R + is the dissociation constant, n k 2 R + is the Hill coefficient. When`k = 0, 8k 2 {1, ..., m}, the dynamics are unstable.
A control theoretic algorithm for designing treatment strategies
To design treatment strategies that best minimize tumor size and control its evolution over time, we combine both a greedy algorithm and receding horizon control approach. We introduce some notation, cost function definitions and specify our algorithm.
Cost functions
To measure the effectiveness of a given treatment strategy over time, we define the average cost function. For a given treatment strategy`k applied to Equation (S1), we rewrite the dynamics of the entire system (i.e., for all cells) asẋ
where A 2 R n⇥n is a matrix that represents the growth, mutation and drug dynamics for treatment strategy`k, for n cell subpopulations.
The average cost C r for a time horizon N , allowable switching period ⌧ and time intervals of the form [k⌧, (k + 1)⌧ ] for k = {0, .., N/⌧ 1} is given by
where 1 T is the n ⇥ 1-dimensional vector of ones and x(t) is the solution to Equation (S3). Equation (S4) simplifies to
The final cost C f for an inital tumor population x(0) and a sequence of drugs {`(k)}
that define a switching therapy over a time horizon N is defined as
Algorithm
Our algorithm is defined as follows. Given an initial tumor population, denoted by x 0 , a time horizon N and an allowable switching period ⌧ , we perform the following computations to determine a candidate treatment strategy: that define a switching therapy.
The resulting switching therapy {`(k)} is then applied until the next biopsy can be taken, giving a new tumor cell population measurement, at which point the algorithm is repeated. In particular, it is important that the horizon N be chosen to be longer than expected periods between biopsies.
Model Implementation and Simulations
Derivation of dynamical system parameters
Growth and Mutation Rates. We model the growth of NSCLC cell population x i by the following ordinary differential equation (ODE):ẋ
where r i is the growth rate per day, andẋ i denotes the derivative with respect to time of the tumor cell population x i . Note that we assume that no mutations occur over the time-frame considered, allowing us to set q ii = 1 and q ij = 0 in the dynamic model (S1), resulting in (S7). Given an initial population x i (0), the population x i (t) on day t can be obtained by solving ODE (S7), and is specified by the following expression
Given a set of N experimental data points e i (0), e i (t 1 ), . . . , e i (t N ), we fit these points to an exponential function of the form (S8), with x i (0) = e i (0) to obtain an experimentally derived value for the growth rate r i of tumor cell population x i .
We take the DNA mutation rate to be 1e 9 mutation/base pair/cell division []. We assume that mutations occur unidirectionally from EGFR L858R parental cells to EGFR L858R,T790M , EGFR L858R , BRAF V600E or EGFR L858R,T790M BRAF V600E , HGF-/+.
Drug Effect Rates and Hill Functions. We model the change in a tumor cell population x i under a treatment j of concentration`with the following ordinary differential equation (ODE):
where r i is the growth rate per day derived in the previous section and f j i (`) is a function mapping the treatment j at concentration`to a drug effect rate per day. We again assume that no mutation occurs over the time-frame considered, allowing us to set the mutation rates q ii = 1 and q ij = 0 in the model (S1), resulting in (S9).
Similar to the previous section, given an initial population x i (0), the population x i (t) on day t can be obtained by solving ODE (S9), and is specified by the following expression
(S10)
We model the map f j i (`) as a modified function of the form
where j,i n j,i and K j,i are the saturation parameter, Hill function coefficient and binding reaction dissociation constant for drug j applied to cell x i . Our goal is to obtain values for these three parameters using experimental data measuring cell viability under varying concentrations`of drug j. In particular, given experimentally obtained data pairs of the form , y i,j,`( 1), where y i,j,`( 1) is the ratio of the tumor cell population x i treated with concentration`of drug j at day 1 to the tumor cell population x i treated with no drug at day 1. Letting xì denote the treated tumor population and xc trl denote the untreated control tumor population, it follows that y i,j,`c an be written as
where the first equality follows from the definition of y i,j,`( 1), the second from applying equations (S10) and (S8) to xì (1) and x ctrl i (1) respectively, and the third from canceling like terms. It follows that the experimentally derived values of f j i (`) are given by
Solving this equation for each experimentally tested concentration`, we obtain a set of points {`, f j i (`)} that can be used to derive the parameters j,i n j,i and K j,i via curve fitting. In order to avoid overfitting, we set j,i = max`f j i (`), i.e., we force the modified Hill function to saturate at the maximal experimentally observed rate. Although this approach can be conservative in modeling the drug effect rate of high concentrations of drugs, we note that the the maximal dose tested is chosen to be significantly higher than the maximum tolerated doses, and hence we do not expect this saturation to affect the accuracy of our model at clinically relevant doses. where x 2 R n is a vector of concentrations of n NSCLC subpopulations,ẋ 2 R n is their rate of change over time, A 2 R n⇥n is a matrix that represents the growth and mutation dynamics and D`2 R n⇥n is a diagonal matrix that represents the corresponding drug effect of one constant drug treatment on the rate of change of NSCLC cells. If all eigenvalues are negative then Equation (S14) is said to be stable. In the case of NSCLC evolutionary dynamics corresponding to Equation (1), stability refers to tumor reduction, and instability refers to tumor progression. In section 3.1, we made the assumption that mutation rates are one directional, hence the A matrix in Equation (1) is lower triangular and the eigenvalues of A D`are exactly equal to its diagonal entries. For each NSCLC subpopulation, we take the maximum eigenvalue for each evolutionary branch downstream of the population and define this as evolutionary stability. This maximum eigenvalue represents the worst case stability if the particular population is present upon treatment initiation -a positive maximum eigenvalue indicates that the presence of the cell subpopulation in the tumor upon initiation of treatment is likely to cause therapeutic failure. A negative maximum eigenvalue indicates that the presence of the particular subpopulation will not outgrow or evolve in the presence of therapy.
Evolutionary stability measured by maximum eigenvalues
Robustness analysis
Sensitivity to drug perturbations. To analyze the effect of dose reductions on the robustness of constant and switching treatment strategies, we perturbed the drug concentrations and calculated the ratio of final cost and initial cost (Figures (S8) ) . We rewrite Equation (S1) for one cell x i and one drug`j to illustrate how a drug perturbation 2 R [0,1] is modeled:
The fold change F C f in total population from day 0 to day N for a sequence of drugs {`(k)} N/⌧ 1 k=1 defining a switching strategy over a time horizon N , and initial tumor population x 0 = x(0) is calculated by
If F C f < 1, the treatment strategy {`(k)}
is effective for NSCLC populations for the duration of the time horizon N , F C f > 1 indicates progression.
Implementation
The evolutionary dynamics model and simulations were implemented using python, scipy and numpy (versions 3.5.1, 0.17.0, 1.9.3) and pandas version 0.17.0 was used for data parsing. Data fitting for experimentally derived cell growth and drug dose response data was performed with Matlab version 8.3.0.532 using the non linear least squares method. Figure S1 : Experimentally derived erlotinib, afatinib, vemurafenib, trametinib and crizotinib dose response curves for 11-18 EGFR L858R , 11-18 EGFR L858R BRAF V600E , H1975 EGFR L858R,T790M H1975 EGFR L858R,T790M BRAF V600E cell lines, and either 0 or 50 ng/ml human growth factor (HGF) and fit with
[`] n
[`] n +K n where is the maximum inhibition, [`] is the EGFR TKI concentration, n is the Hill coefficient and K is the half maximal inhibitory concentration (IC50). Figure S2 : Experimentally derived dose response curves for erlotinib in combination with 5 µM vemurafenib, 0.5 µM trametinib and 0.5 µM crizotinib for 11-18 EGFR L858R , 11-18 EGFR L858R BRAF V600E , H1975 EGFR L858R,T790M H1975 EGFR L858R,T790M BRAF V600E cell lines, and either 0 or 50 ng/ml human growth factor (HGF) and fit with
[`] n +K n where is the maximum inhibition, [`] is the EGFR TKI concentration, n is the Hill coefficient and K is the half maximal inhibitory concentration (IC50). Figure S4 : A) Experimentally derived dose response curves for afatinib in combination with 5 µM vemurafenib, 0.5 µM trametinib and 0.5 µM crizotinib for 11-18 EGFR L858R , 11-18 EGFR L858R BRAF V600E , H1975 EGFR L858R,T790M H1975 EGFR L858R,T790M BRAF V600E cell lines, and either 0 or 50 ng/ml human growth factor (HGF) and fit with
[`] n +K n where is the maximum inhibition, [`] is the EGFR TKI concentration, n is the Hill coefficient and K is the half maximal inhibitory concentration (IC50). (B) Western blot analysis of cell lysates obtained from H1975 cell lines, treated with drugs and/or HGF as indicated, and probed for the indicated proteins. Figure S6 : Simulations of the NSCLC model for the optimal 30 day constant combinations found by Algorithm (4) with 0.5 µM afatinib or 1.5 µM erlotinib with either 0.5 µM trametinib, 0.5 µM crizotinib or 5 µM vemurafenib for the relatively low (A) initial tumor heterogeneity or with (B) high initial tumor heterogeneity. Figure S7 : Classification of initial tumor compositions via eigenvalue decompositions describe the initial tumor populations that can destabilize of the evolutionary dynamics in the presence of either erlotinib or afatinib and either 0.5 µM trametinib, 0.5 µM crizotinib or 5 µM vemurafenib. Figure S8 : A) Fold change in NSCLC population at day 30 versus day 0, over the course of the optimal 30, 15, 10, 5, 3, and 1 day treatment strategies solved by algorithm 1 (SI), for indicated tumor compositions, normalized by fold change in NSCLC population for the constant 30 day treatment strategy (Red). (Blue) Sum of fold change in the average cost for indicated tumor compositions and corresponding optimal 30, 15, 10, 5, 3, and 1 day treatment strategies. B) (Above) Fold change in number of NSCLC cells between day 0 and day 30, as a function of percent EGFR TKI dose reduction for the optimal 30, 15, 10, 5 and 1 day strategies solved by algorithm 1 (SI) for indicated tumor compositions. Shaded blue areas indicate the region of the perturbation space where the treatment strategy reduces the size of the initial tumor (stable). The shaded red area indicates the region of the perturbation space where the treatment strategy increases the size of the original tumor at day 30 (unstable). (Below) The maximum percent EGFR TKI dose reduction sustainable before the treatment is no longer effective (the tumor progresses). Table 4 : Drug sensitivity as measured by the IC50 of afatinib in combination with 5 µM vemurafenib, 0.5 µM trametinib and 0.5 µM crizotinib in parental and engineered 11-18 EGFR L858R -positive lung adenocarcinoma cells. Table 7 : Differential equation parameters as derived using Equation (S11), corresponding to experimentally derived dose response curves of erlotinib in combination with either 0.5 µM crizotinib, 0.5 µM trametinib or 5 µM vemurafenib for parental and engineered 11-18 EGFR L858R -positive lung adenocarcinoma cells. Table 8 : Differential equation parameters derived using Equation (S11), corresponding to experimentally derived dose response curves of afatinib in combination with either 0.5 µM crizotinib, 0.5 µM trametinib or 5 µM vemurafenib for parental and engineered 11-18 EGFR L858R -positive lung adenocarcinoma cells.
